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Introduction
Urinary bladder cancer (BCa) accounts for about 5% of 
all new cancers in the United States with estimated 74,960 
new cases and 16,390 deaths in 2016 (1). Rates for new 
BCa cases have been decreasing on average by 0.8% per 
year over the last 10 years; death rates have been, on the 
other hand, stable over 2004–2013. The 5-year Relative 
Survival has only marginally improved from 71.5% to 
77.5% from 1975 to 2008 (2), indicating a gap between 
diagnosis and management of these patients. Indeed 
such minor improvement is likely due to other reasons 
than improvements in treatment (3,4). Today, in western 
countries still, 10−15% of BCa patients present with 
metastatic disease (5). In addition, nearly half of patients 
with muscle-invasive bladder cancer (MIBC) will eventually 
relapse after radical cystectomy (RC) (6). Almost all 
patients who succumb to BCa have disseminated and often 
symptomatic metastasis at time of death (7,8). Generally, 
the outlook of these patients is poor and treatment is mostly 
palliative in nature. It is worthwhile to mention that there 
are no major advances achieved in the last three decades but 
newer advances such as immunotherapeutic and targeted 
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therapies promise to change this status quo significantly. 
To understand how to help patients today best and to assess 
the possible interactions between todays and tomorrows 
therapies, there is a need for well-designed analysis of our 
current knowledge of the natural history of this disease 
state, of available treatment strategies and of possible 
therapeutic alternatives for this subset of patients (9,10).
Overview of management of muscle invasive BCa
RC with pelvic lymph node dissection (PLND) is the 
standard treatment for patients with non-metastatic MIBC 
(cT2-T4a, cN0-Nx,M0) (6) and patients with very high-risk 
non-muscle invasive BCa (11). The 5-year overall survival 
(OS) rates were estimated to be around 60% (12-14), ranging 
from 32% in patients with lymph node involvement to 75% 
in those without (15). RC includes pelvic lymphadenectomy 
as an integral part of the procedure with better oncological 
outcomes in patients with N0M0 MIBC. Indeed, lymph 
node status is the single most powerful pathologic 
predictors of long term disease-specific survival (DSS) and 
OS, but the exact extent of PLND is a matter of debate 
with on-going randomized trials adding new knowledge 
soon (13,14,16,17). Despite radical treatment, the incidence 
of distance failure in clinically non-metastatic patients with 
organ confined, extravesical and lymph node positive disease 
were estimated to be 25%, 37% and 51%, respectively (18). 
This is attributed to the presence of micrometastasis that 
remains undiagnosed at the time of surgery (14).
About one fourth of patients who undergo RC and 
PLND have concomitant lymph node metastasis; the 
rate of involvement increases with increasing tumor stage 
(14,17,19). Node positive disease carries a worse prognosis 
with 5-year recurrence-free survival (RFS) rates in the 
range of 4–35% (13,14,17). RC with extended PLND alone 
can provide long term RFS in approximately 25% patients 
with lymph node metastasis. However, this is mostly true 
in a small subgroup of lymph node positive patients with 
localized disease and limited lymph node metastatic burden. 
Consequently, this finding does not obviate the need of 
perioperative systemic therapy (14,20). Before discussing 
management strategies of MIBC, locally advanced and 
metastatic BCa, it is prudent to mention that a radiological 
evaluation should take place before any treatment with 
curative intent to accurately stage the disease and to identify 
patients with locally advanced and/or metastatic disease. 
The EAU guidelines recommend computed tomography 
(CT) of the chest, abdomen and pelvis as the optimal 
radiological staging for patient with MIBC. Accurate clinical 
staging is of utmost importance for patient counselling, 
prognostication and treatment planning. Unfortunately, 
up- and down-staging are not uncommon existing in a 
range of 27–62%. This discrepancy between clinical and 
pathological staging is caused partially by inaccuracy of 
radiological tools and represents one of the most important 
barriers to improvement treatment strategies (19,21).
It is also important to emphasis the importance of 
accurately predicting patient prognosis and the expected 
outcome of selected treatment for proper counselling and 
treatment planning. These information are fundamental 
for treating physicians and patients, especially when based 
on solid and comprehensive data. A well-informed patient 
can take part in decision-making process depending on 
individualized risk estimation. Developing and adopting 
validated nomograms (especially when incorporating 
molecular markers) represent major advancement in this 
field as it provides more discriminating and accurate 
predicting tool over the currently adopted AJCC staging 
system which relies only on stage, lymph node status and 
presence of metastasis (7).
Role of neoadjuvant chemotherapy (NAC)
In the landmark phase III randomized intergroup clinical 
trial conducted by the Southwest Oncology Group (SWOG 
S8710) in patients with MIBC T2−T4aN0M0, Grossman et al. 
demonstrated that the estimated risk of death is reduced by 
25% in patients receiving three cycles of M-VAC NAC plus 
RC compared to RC alone. The trial also proved that patients 
who had been down-staged to pT0 had a better survival 
than those who did not achieve complete response (22). 
An update of the advanced bladder cancer (ABC) meta-analysis 
collaboration systematic review and meta-analysis based on 
11 trials with 3,005 patients supported this beneficial effect of 
NAC over definitive local therapy alone with a 14% reduction 
in the estimated risk of death compared to definitive local 
therapy alone. This is also equivalent to an absolute survival 
benefit of 5%, improving OS from 45% to 50% at 5 years (23). 
NAC was not associated with increased risk of death, did not 
affected the patients’ chance of undergoing RC (22) and did 
not increase perioperative morbidity (22,24,25). Despite that 
and the compelling level 1 evidence, NAC is still underutilized 
and treatment is often with RC alone or RC with adjuvant 
chemotherapy (AC) (26,27).
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The effect of surgical factors on local recurrence 
and survival outcomes
Herr and colleagues performed secondary analysis of the 
patients who had RC in the SWOG 8710 trial with the 
aim of identifying the surgical variables associated with 
survival outcomes. The investigated variables were margin 
status, total number of lymph nodes examined, extent 
of PLND, type of institution (academic, community, or 
Veterans Affairs), type of urinary diversion and whether the 
surgeon was a general urologist or an onco-urologist. They 
found that surgical variables were associated with local 
recurrence and survival outcomes in patients with locally 
advanced BCa whether or not they received NAC. Positive 
surgical margins and number of lymph nodes removed 
(cutoff of 10) were found to be independently associated 
with local recurrence and worse survival after adjusting for 
the effects of treatment type, pathological stage and lymph 
node status. Testing the association between treatment 
and number lymph nodes removed or margin status was 
not statistically significant. Type of surgeon and institution 
were not associated with local recurrence or OS survival. 
Nevertheless, when number of lymph node removed 
and the status of margin were tested in a multivariable 
model adjusted for the effects of other variables, the type 
of surgeon (general urologist) and the institution (non-
academic) independently predicted removal of less than 
ten lymph nodes and positive surgical margins. Similarly, 
type of surgeon and institution were also associated with 
type of diversion with less experienced centers tending 
to ileal conduits more often. PLND as a variable was not 
found to be independently associated with survival and 
local recurrence; the authors suggested that the numbers of 
lymph nodes are more accurate than the extent of PLND (28).
The results of this secondary analysis were interesting 
in different ways. First, this analysis suggested that the 
quality of surgery influenced the oncological outcomes; it 
was indeed more important than whether patients received 
NAC or not. Secondly, the quality of surgery was influenced 
by the work focus of the surgeon and the type of institution. 
Third, NAC treatment did not affect the surgical factors. 
These findings address important aspects in our efforts to 
improve cancer management, not only in BCa, but also 
other tumors such as surgical training with greater emphasis 
on the role of well-structured training programs, sub-
specialty training, quality control of oncological surgery, 
referral to high volume center and/or surgeons, and adding 
the quality of surgery into future models to measure the 
actual effect on treatment. 
Clinically positive lymph nodes
Although NAC has been shown to be associated with 
improved survival in randomized clinical trials (22,23,29), 
most trials did not include patients with clinically node 
positive disease (cN1-3). For example, the ABC Meta-
analysis Collaboration included only 4% of patients with 
cN1/cN2 and 48% with unknown N stage (cNx). In 
patients with clinically positive lymph node metastasis, 
systemic chemotherapy may be given as the primary therapy 
followed by RC with bilateral PLND as a consolidation 
therapy only in those patients who achieve notable 
response (30). A multi-center analysis of the outcomes 
of 304 patients with clinically positive lymph nodes who 
underwent primary chemotherapy using different regimens 
and RC as a consolidation therapy showed that almost 
half of patients achieved pN0 and about one quarter 
converted to pT0 after induction six cycles instead of three 
or four cycles chemotherapy. The pathological complete 
response (pCR) rate was 14.5%. The median OS was 
22 months and survival was significantly better for patients 
who achieved complete nodal response, had negative 
surgical margins at time of RC and underwent excision 
of 15 or more lymph nodes. In addition, there was no 
statistically significant difference in outcomes between the 
MVAC and the GC regimen (30). Nieuwenhuijzen et al. 
evaluated the response and survival outcomes of 52 patients 
with histologically proven lymph node metastasis treated 
with chemotherapy followed by post chemotherapy surgery 
after achieving partial or complete response. Complete 
response was independently associated with DSS yielding 
5-year survival rates of 42%. Additionally, lymph node 
response was found to be more important than local tumor 
response as no patient with node positive disease after 
chemotherapy achieved 2-year survival. Even in patients 
with partial response, post-chemotherapy surgery resulted 
in 5-year DSS of 19% (31). Other studies described higher 
rates of pCR (32,33) and lower OS time (31,33). 
The effect of complete clinical and pathological 
response
In a study that described the natural history in 109 patients 
who achieved complete clinical response after combination 
cisplatin-based chemotherapy, 29% achieved cT0. Then, 
7 patients chose immediate RC and 25 chose active 
surveillance. Three fourth of patients who opted for 
surveillance preserved their bladder at a median follow 
up time of 55 months with CSS rates of 88% at 5 years 
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including patients who underwent delayed RC for disease 
recurrence or progression. Immediate RC was not found 
to be significantly different from delayed RC in term of 
survival outcomes. However, this study has to be judged 
with caution because of its small sample size and possible 
selection bias. Nevertheless, it supports the importance of 
prediction of outcomes in patients who achieve cT0; as this 
is a heterogeneous population with a proportion benefitting 
from bladder-sparing active surveillance and others 
needing completion RC to ensure long term survival (34). 
Of the 126 patient who received three cycles of NAC in the 
SWOG S8710 trial, 38% of the surgical specimens were 
(pT0) (22). A meta-analysis of 13 trials evaluating the effect 
of pCR in primary tumor as well as lymph nodes after NAC 
showed that a pCR rate of 29% and a relative risk for RFS 
of 0.19 (P<0.00001) and for OS of 0.45 (P<0.00001) (35). 
These data underline the efficacy of cisplatin-based 
combination chemotherapy and for now the need for 
completion RC until better stratification is possible.
Intraoperative finding of enlarged lymph nodes
Herr et al. reported on a series of 84 patients with grossly 
enlarged resectable lymph node at time of RC and PLND. 
The median survival was 19 months and about one fourth 
of patients achieved long term survival of 10 years. They 
concluded that if PLND can be performed completely and 
safely, it is better to proceed with RC and PLND (36). 
AC 
An updated systematic review and meta-analysis of nine 
randomized controlled trials that included 945 patients 
demonstrated survival advantages in patients who received 
AC; 22% and 34% relative reduction in the risk of death 
and disease recurrence, respectively. Interestingly, there was 
a greater absolute benefit among those with positive nodal 
involvement in terms of disease-free survival (37). Also, a 
large international study that included more than 1,500 
patients with lymph node positive disease after RC reported 
17% relative risk reduction in CSS in those who received 
adjuvant cisplatin-based combination chemotherapy 
compared to those who underwent surgery alone (26). A 
randomized trial that recruited 284 patients showed no 
significant OS benefit in patients receiving immediate AC in 
comparison to patients who received deferred chemotherapy 
(at time of relapse) in pT3–pT4 and/or node positive 
(pN1–3) M0 disease. Nevertheless, a significant PFS 
advantage was noted in favor of immediate chemotherapy 
group (38). This study failed to accrue the planned number 
of patients (284 of the planned 660) and therefore remains 
inconclusive. There is no evidence to support the use of 
carboplatin in patients who are ineligible for cisplatin NAC 
or AC; in this case, clinical trial or surveillance in absence of 
clinical trial options may be the best next step (39).
The pattern of relapse in patients who failed RC differs 
from patients with regional metastasis who relapse after 
response to NAC. In the first group, 30% present with 
local recurrence (6), whereas in the second group three-
fourth of patients experience relapse at site of response (40). 
The aforementioned facts and review provide reasonable 
rational for surgery to consolidate chemotherapy (41). 
It is also worth to mention that the presence of nodal 
involvement doesn’t preclude the construction of orthotopic 
neobladder, because the majority of recurrences after RC 
are distant and recurrences (even locally ones) do not 
often affect the functionality of the neobladder (42). The 
EAU guidelines do not, however, recommend orthotopic 
neobladder for N2 and N3 patients (6). 
Management of patients with inoperable locally 
advanced tumour and/or distant metastasis
First line chemotherapy
Approximately, one fifth of BCa present in the industrialized 
countries present with either inoperable or metastatic 
disease (41). In these patients, cisplatin-based combination 
chemotherapy is the standard of care when possible. After 
the introduction of effective chemotherapy, the median 
survival has improved from 3–6 months to more than 
1 year (43). The initial response rate using different regimens 
of first line cisplatin-based combination chemotherapy 
(MVAC, GC, HD-MVAC with G-CSF) is approximately 
40–70% and the median OS is  about 14 months. 
However, the long term survival is poor and most patients 
experience disease progression at a median time of 8 
months. The best response was noted in patients with good 
performance status, adequate renal function, complete 
response and lymph node metastasis compared to those 
harboring visceral metastasis (44). Indeed, approximately 
one fifth of patients with lymph node only disease achieved 
5-year DFS (45,46). Advance patient age, medical co-
morbidities, poor performance status and renal impairment 
are not uncommon in this subset of patients and they do 
not only prevent proper and full delivery of chemotherapy 
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regimens but are also associated with poor outcome (9,46). 
Actually, up to 50% of patients are unfit for cisplatin-based 
chemotherapy (47). For these patients options include 
a carboplatin-based regimen such as carboplatin plus 
gemcitabine or carboplatin, gemcitabine, plus paclitaxel 
or non-platinum based combinations i.e., paclitaxel plus 
gemcitabine (39). Gemcitabine plus carboplatin is the 
preferred regimen because of the lower rate of severe 
systemic toxicity (47). However, none of these regimens 
have any significant response rate. The promise lies in 
novel immunotherapeutics which seem to have substantial 
response rates regardless of the patient’s renal function.
Second line chemotherapy  
Patients who experience disease progression or relapse after 
first-line chemotherapy carry dismal prognosis. In the US, 
a commonly used salvage systemic therapy is single agent 
taxane chemotherapy with OS of 6–9 months. A recent 
phase II trial, comparing combination taxane-containing 
combination chemotherapy versus single-agent taxane, in 
patients who failed prior platinum-based chemotherapy, 
showed improved OS in the combination group (48). In 
Europe, vinflunine is the standard in this disease state. It 
has survival advantage over best supportive care alone and is 
recommended by the ESMO and the EAU guidelines as the 
only approved second-line treatment (6,49). In this disease 
state too, immunotherapeutics will change therapeutic 
paradigms yielding better outcomes. 
Surgery as a consolidation therapy 
Patients who respond to primary chemotherapy may 
benefit from surgical consolidation if the disease is limited 
and located in the regional lymph nodes or metastatic 
site/sites amenable to surgical removal (i.e., non-regional 
lymph node and/or some lung metastasis). The concept of 
metastasectomy in urothelial carcinoma was first described 
in the early 1980s, when Cowles et al. reported long-
term survival (median length of 5 years) for six patients 
who underwent wedge resection for solitary pulmonary 
metastasis. After more than one decade, multiple reports 
started to demonstrate the suggested benefits of surgical 
excision of metastatic lesions as part of a multimodality 
approach (50). In the age of immunotherapeutics, reduction 
of tumor burden may become even more important. 
Harry and colleagues assessed the impact of post-
chemotherapy surgery in 80 patients with unresectable 
(T4bNxM0) or inoperable tumor with extensive pelvic 
and/or retroperitoneal lymph node metastasis (T3 to 4, 
N2 to 3, M0 to 1). They found that 32 patients who had 
inoperable disease became resectable after chemotherapy 
with half of them having full resection of residual disease. 
About one third of cases who achieved complete response 
to chemotherapy and surgery survived up to 5 years. 
Patient who had complete response to chemotherapy 
benefitted most from post-chemotherapy surgery (51). In 
a retrospective study, Dodd et al. founded that 30 (60%) 
patients achieved complete response to chemotherapy 
and surgery, of which 10 (33%) remained alive at 5 years. 
Patients with unresectable tumor and regional lymph 
node involvement fared better than patients with visceral 
metastasis (52). Miller et al. also had reported on 55 patients 
with 55% overall complete response rate. They also found 
that patients with visceral metastasis had worse outcome (53). 
Siefker-Radtke and colleagues reported on 31 patients with 
30 undergoing complete resection of metastatic sites; lung 
lesions were the most commonly resected site follow by 
distant lymph nodes. The median survival and 5-year OS 
from time of metastasectomy were 23 months and 33%, 
respectively (54). A multicenter experience from Germany 
reported on 44 patients with metastatic urothelial carcinoma 
who underwent metastasectomy as part of multimodality 
treatment (systemic chemotherapy was administered in 
80% before and/or after surgery). Retroperitoneal lymph 
nodes, distant lymph nodes, lung, bone, adrenal, brain, 
small intestine and skin were the resected metastatic sites in 
descending order. Median CSS and PFS after surgery were 
34 and 15 months, respectively. Lehmann et al. concluded 
that cure is possible, long-term control can be achieved and 
surgery should be part of a multimodality approach (50). 
Abe et al. reported on 48 patients with metastatic BCa 
who received first-line chemotherapy with 20 patients 
undergoing additionally either metastasectomy (lobectomy 
n=7; lymphadenectomy n=3; and local recurrence surgery 
n=2) or second line chemotherapy. They found that the 
number of chemotherapy cycles (five or more), resection 
of metastases, and site of metastasis (absence of local 
recurrence, bone or liver recurrence) were independently 
associated with prolonged survival (55). Taken together, 
we believe that metastasectomy, in selected patients, may 
be attempted in a shared decision making process with the 
patient. At this time, it seems that lymph node and lung are 
the best sites and that a complete response to chemotherapy 
improves the odds of benefiting from the surgery; 
performance status is certainly a key criteria.
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Non-regional lymph node resection 
(metastasectomy)
According to TNM classification, lymph node involvement 
above the bifurcation of common iliac arteries is classified 
as distant metastasis (56). For patients with lymph node 
metastasis above true pelvis (without synchronous visceral 
metastasis), upfront chemotherapy followed by consolidation 
surgery in patients with good response is becoming an 
accepted strategy. Sweeney et al. reported on 11 patients with 
non-regional lymph node metastasis without synchronous 
visceral involvement who underwent bilateral retroperitoneal 
lymph node dissection (RPLND) as a consolidation therapy 
after major response to chemotherapy; 7 out of 11 patients 
underwent metastasectomy simultaneously with RC. The 
median RFS was 7 months and the 4-year DSS rate was 36%. 
Based on their results, they concluded that RPLND is safe and 
potentially curative, especially in patients with no more than 
two lymph nodes with viable tumor after chemotherapy (57). 
Another series included 14 patients with supra-regional (para-
aortic and para-caval) lymph node metastasis; all patients 
underwent four cycles of cisplatin-based combination 
chemotherapy followed by RC with a complete pelvic and 
retroperitoneal lymphadenectomy. They found that one 
fourth of patients survived 5 years using this approach (56). 
Although these series are small and consist of well-selected 
patients, one can appreciate the role of post-chemotherapy 
surgery. The challenge will be to choose the right patient 
and to balance complications with survival outcomes in 
harmony with patients’ wishes.
Pulmonary metastasectomy
A study from Japan assessed the factors associated with 
prolonged survival in 18 patients with urothelial carcinoma 
who underwent pulmonary metastasectomy for limited 
metastatic sites/sites. They identified solitary metastasis as a 
factor associated with long-term survival; 5-year survival was 
85% compared to 20% for patients with multiple metastasis 
(P<0.05). Complete resection was possible in 16 patients with 
no operative mortality. The cumulative 5-year OS in this 
series was 47% (58). 
The aforementioned overview supports the concept that 
resection of limited metastatic deposits is feasible, safe and 
may be beneficial. However, solid evidence is lacking and 
recommendations cannot be made since the cohorts are too 
heterogeneous and small with retrospective study design. 
Refractory metastatic disease 
A phase II trial enrolled 70 patients with refractory 
metastatic BCa (not responding to MVAC chemotherapy) 
to assess the outcome of complete surgical resection of 
metastatic sites. They found that the median survival was 
7 months with no survival advantage for metastasectomy 
regardless of the site of metastasis. An advantage was noted 
in the quality of life of patients who had symptomatic 
metastasis but not in those who harbored asymptomatic 
disease who actually, in turn, complained from reduced 
sense of well-being after the surgery (59).
RC as sole therapy
Perioperative complications and outcome were evaluated in 
a series of 20 consecutive T4 patients who were subjected 
to primary RC. In only one patient complete resection 
was not accomplished (macroscopic soft tissue margin) 
and three patients had microscopic soft tissue margins on 
histopathological examination. Half of the patients died 
within a mean interval of 7 months after surgery. The 
authors concluded that RC is technically possible with 
acceptable perioperative morbidity. Their rational was 
that NAC would delay delivery of definitive local therapy 
to a point where local growth may make the tumour 
unresectable (60). However, the sample size was small 
and the follow up was too short to draw any significant 
conclusion. In addition, their rationale has been refuted, 
as cisplatin-based combination chemotherapy is effective 
and may even downstage the tumour (32). Moreover, these 
patients are most likely to benefit from systemic therapy 
and are most likely to be administrable in the neoadjuvant 
setting (61).
Salvage RC
Salvage RC is recommended for tumour recurrence after 
bladder-sparing approaches (6). It is estimated that between 
25–45% of patients who initially select multimodality 
bladder-sparing therapy ultimately undergo salvage RC (62). 
Type of bladder preserving approach, pathological tumor 
stage and lymph status remain the strongest prognostic 
factors for survival outcomes after salvage RC (18,63,64). 
Salvage RC outcomes after partial cystectomy were 
evaluated in 72 patients with a median follow-up time of 
10.9 year. Bruins and colleagues reported that extravesical 
741Translational Andrology and Urology, Vol 5, No 5 October 2016
Transl Androl Urol 2016;5(5):735-744tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
extension and lymph node metastasis were independently 
associated with disease recurrence and only 22% of those 
patients were salvaged by surgery after 5 years compared to 
36% for patients who underwent immediate RC from the 
baseline cohort of 2,218 patients (65). Salvage RC was found 
to be associated with more complication rate than immediate 
RC. When complications were stratified into perioperative 
(within 90 days) and delayed, the immediate RC group had 
significantly higher cardiovascular complications (myocardial 
infarction, deep vein thrombosis, pulmonary embolism and 
blood transfusion) than the salvage RC group who had higher 
rates of wound infection, fascial dehiscence, anastomotic 
stricture and stomal revision (64). 
Palliative cystectomy
Patients with bladder tumour fixed to pelvic or abdominal 
wall (pT4b) and those with intractable bleeding may suffer 
from severe symptoms that necessitate intervention. Due to 
its high morbidity, surgery is not the first option and should 
be taken into consideration after failure of less invasive 
options such as palliative radiotherapy as the cancer-related 
life expectancy of these patients is very limited (6). 
Conclusions 
BCa is a chemosensitive tumour and chemotherapy is the 
mainstay of treatment for metastatic disease state. However, 
this is rarely curative and most patients succumb eventually 
to their disease. There has been no major advance in the 
management of these patients since the introduction of 
cisplatin-based combination chemotherapy. Indeed, the 
5-year survival for metastatic BCa has not improved over 
the last decades. Therefore, management of metastatic 
BCa represent a great challenge regarding accurate clinical 
staging, risk stratification and cancer control requiring new 
treatment strategies.
In non-metastatic disease, RC is the standard therapy 
for improving survival. The role of PLND is still today, 
especially in high-risk patients, an essential part of the 
procedure. What remains to be addressed is the extent 
of lymph node dissection and the optimal candidates for 
perioperative chemotherapy.
In the metastatic disease state, surgery may be beneficial 
as a part of a multimodality approach resulting in long term 
survival in selected patients. The advantage appears to be in 
patients with complete or major response to chemotherapy 
and those who have metastasis in site/sites that are 
amenable to surgical resection, especially non-pelvic lymph 
nodes and lung metastasis. However, the evidence for RC 
and/or metastasectomy remains limited requiring larger, 
multicentre collaborations with homogenous patient 
population. Prospective randomized clinical trials and 
validated nomograms that incorporate molecular markers 
and/or quality of surgery to predict disease outcome and to 
balance risk distribution may help further refine evidence 
creation in this heterogeneous disease state. 
With the advent of immunotherapeutics in urothelial 
carcinoma, we are at the beginning to live through a time 
with a radical change awaiting us in the management of 
micro-and macro-metastatic disease. We foresee here a 
radical change in the role of surgery in metastatic setting. 
There is no doubt that we need to do better in locally 
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